NOVATO, Calif., Feb. 12 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical
Inc. (Nasdaq: BMRN) announced today that in the first interim efficacy
analysis (IEA) for the Riquent(R) Phase 3 ASPEN trial, the Independent Data
Monitoring Board (DMB) determined that the continuation of the trial is
futile. BioMarin and partner La Jolla Pharmaceutical have decided to stop the
study, unblind the data and evaluate all of the clinical results including
secondary endpoints such as SLE (Systemic Lupus Erythematosus) disease
activity indices and proteinuria.

"While the results of this first interim efficacy analysis are obviously
disappointing, we decided to take a calculated risk on this program and with
the carefully staged agreement, we have spent a total of $15 million, a
relatively modest amount for a late Phase 3 asset addressing a large market
opportunity," said Jean-Jacques Bienaime, Chief Executive Officer of BioMarin.
"We remain dedicated to advancing our development pipeline by making
investments in future growth and continue to look for attractive late-stage
in-licensing or acquisition opportunities."

About BioMarin

BioMarin develops and commercializes innovative biopharmaceuticals for
serious diseases and medical conditions. The company's product portfolio
comprises three approved products and multiple clinical and preclinical
product candidates. Approved products include Naglazyme(R) (galsulfase) for
mucopolysaccharidosis VI (MPS VI), a product wholly developed and
commercialized by BioMarin; Aldurazyme(R) (laronidase) for
mucopolysaccharidosis I (MPS I), a product which was developed through a 50/50
joint venture with Genzyme Corporation; and Kuvan(R) (sapropterin
dihydrochloride) Tablets, a product for the treatment of phenylketonuria
(PKU), developed in partnership with Merck Serono, a division of Merck KGaA of
Darmstadt, Germany. Other product candidates include 6R-BH4 for cardiovascular
indications, which is currently in Phase 2 clinical development for the
treatment of sickle cell disease, and PEG-PAL (PEGylated recombinant
phenylalanine ammonia lyase), which is currently in Phase 1 clinical
development for the treatment of PKU. For additional information, please visit
http://www.BMRN.com. Information on BioMarin's website is not incorporated by
reference into this press release.

Forward-Looking Statement

This press release contains forward-looking statements about the business
prospects of BioMarin Pharmaceutical Inc., including, without limitation,
statements about: expectations related to the clinical trials and continued
development of abetimus sodium, also known as Riquent. These forward-looking
statements are predictions and involve risks and uncertainties such that
actual results may differ materially from these statements. These risks and
uncertainties include, among others: results and timing of current and planned
preclinical studies and clinical trials, including the ASPEN study; the
enrollment rate of such study and the actual rate of renal flares in such
study; the content and timing of decisions by the U.S. Food and Drug
Administration, the European Commission regarding abetimus sodium; La Jolla
Pharmaceutical's ability to and success in executing the ASPEN study and its
ability to produce sufficient quantities of material for such study; and those
factors detailed in BioMarin's filings with the Securities and Exchange
Commission, including, without limitation, the factors contained under the
caption "Risk Factors" in BioMarin's 2007 Annual Report on Form 10-K, and the
factors contained in BioMarin's reports on Form 10-Q. Stockholders are urged
not to place undue reliance on forward-looking statements, which speak only as
of the date hereof. BioMarin is under no obligation, and expressly disclaims
any obligation to update or alter any forward-looking statement, whether as a
result of new information, future events or otherwise.

(Date:11/19/2016)... 2016 Securus Technologies, a leading provider of ... investigation, corrections and monitoring, announced today that it has ... have an independent technology judge determine who has the ... tech/sophisticated telephone calling platform, and the best customer service. ... most of what we do – which clearly is ...

(Date:11/15/2016)... 15, 2016 Synthetic Biologics, Inc. (NYSE MKT: ... on the gut microbiome, today announced the pricing ... of its common stock and warrants to purchase ... price to the public of $1.00 per share ... from the offering, excluding the proceeds, if any ...

(Date:6/27/2016)... Research and Markets has announced the addition ... to their offering. The report ... to grow at a CAGR of 12.28% during the period 2016-2020. ... in-depth market analysis with inputs from industry experts. The report covers ... The report also includes a discussion of the key vendors operating ...